drugset / Trial / NCT05761951
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
Phase 2
Active not recruiting
8 enrolled
M.D. Anderson Cancer Center
Leap Therapeutics, Inc. · collabMerck Sharp & Dohme LLC · collabNational Cancer Institute (NCI) · collab
RandomizedSingle-groupOpen-labelTreatment
Summary
To learn if the combination of DKN-01 and pembrolizumab can help to control advanced or recurrent endometrial cancer.
Timeline
- Start
- 2023-08-29
- Primary completion
- 2027-01-31
- Completion
- 2029-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DKN-01 | Monoclonal antibody | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |